Andrew Shaoyu Chen

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

China Life Sciences: 2024 Year In Review

Landmark Whistleblower Program For China's Healthcare Sector: Proposed Maximum Reward Of 1 Million RMB

Compliance With China's Drug Marketing Authorization Holder Local Agent And Registration Agent Requirements 药品上市许可持有人境内代理人与注册代理人的合规要求

A New Milestone In China's Regulation Of Human Genetic Resources 中国人类遗传资源监管的新里程碑

China Proposes To Prohibit Export Of Certain Human Cell Cloning And Gene Editing Technologies

Navigating The Latest Changes In China's Regulation Of Human Genetic Resources 应对中国人类遗传资源监管新的最新变化

New Developments In China's Drug Change Management Regulations

China Plans To Establish A Drug Patent Linkage System

Navigating The Latest Challenges Of China's Human Genetic Resources Regulation